EVEROTAS 10MG TABLETS | EVEROLIMUS | MHP

1
EVEROTAS 10MG TABLETS
EVEROLIMUS MHP

•  Million Health Pharmaceuticals

2
SYNOPSIS

• DESCRIPTION
• PRESCRIBING INFORMATION
• MECHANISM OF ACTION
• EVEROTAS 10Mg
• PRODUCT DETAILS
• PHARMACOKINETICS
• DOSAGE MANAGEMENT
• PRECAUTIONS
•  SIDE EFFECTS
• DRUG INTERACTION
• CONTRAINDICATIONS
• PREGNANCY
• LACTATION
• STORAGE
• MISSED DOSE
• OVERDOSAGE
• CONTACT US

3
DESCRIPTION

• Everotas 10mg is a derivative of Rapamycin
  (sirolimus) and works similarly to Rapamycin as
  an mTOR (mammalian target of rapamycin)
  inhibitor. 
• It is normally used as an immunosuppressant to
  prevent rejection of organ transplants. In a
  similar fashion to other mTOR inhibitors
  Everolimus' effect is solely on the mTORC1
  protein and not on the mTORC2 protein.

4
Renal carcinoma
5
PRESCRIBING INFORMATION

• Everotas 10mg tablet are mainly indicated for the
  treatment of Renal carcinoma.
• Everotas 10mg  are mainly indicated for the
  treatment of Breast carcinoma.
• Everotas 10mg tablet are mainly indicated for the
  treatment of Brain carcinoma.
• Everotas 10mg is also used in various advanced
  stage cancer in stomach, intestines or pancreas.

6
Breast carcinoma
7
MECHANISM OF ACTION

• Everolimus is an mTOR prohibitor, joints at high
  compatibility to FK506 binding protein 12, via
  producing drug complex which inhibits the
  specific of mTOR.
• This inhibition decreases the activity of
  effectors downstream, that may cause blockage of
  cell progression from G1 into S phase,
  subsequently causes cell growth arrest and
  apoptosis

8
EVEROTAS 10Mg
9
PRODUCT DETAILS

• Brand Everotas 
• Ingredients Everolimus 
• Strength 10mg
• Manufactured Intas pharmaceuticals Ltd 
• Package 10 tablets

10
PHARMACOKINETICS

• ABSORPTION
• The high plasma concentration time of Everolimus
  is 1 to 2 hours.The effect of food with Everotas
  10mg that with heavy meal
• DISTRIBUTION
• Everotas 10mg human plasma protein bound with the
  range of 74.
• METABOLISM
• The metabolism of Everolimus is occurred in
  liver, which is a substrate of CYP3A4.
• EXCRETION
• 5 in urine the parent compound has been
  detected in urine or feces.The half-life period
  of Everolimus is relatively 30 hours

11
DOSAGE MANAGEMENT

• In breast cancer, renal cell cancer, pancreatic
  cancer, Neuro endocrine cancerThe prescribed
  dosage is 10mg should be taken as a single dose.
• In Brain or intracranial cancerThe prescribed
  dosage of Everotas 10Mg is 4.5mg/m2 orally as a
  single dose.
• The usual pediatric dosage of Everotas 10mg in
  brain or intracranial tumor is 4.5mg/m2 should be
  taken orally as a single dose.Everotas 10mg
  tablet should be administered with or without
  food.

12
PRECAUTIONS

• Lymphomas
• Increased exposure of skin cancers, patient may
  protect from UV light
• Serious infections
• Patients receiving Everotas 10mg have high risk
  of acquiring various infections related to
  bacteria, virus, and fungi.
• Hepatic artery thrombosis
• In liver transplant patients, Everotas
  10mg therapy should not be recommended.
• Nephrotoxicity 
• Renal function should be monitored frequently
  caution should be taken while using Everotas
  10mg in renal impaired patients.

13
SIDE EFFECTS

• Hypersensitivity reactions Lymphomas other
  malignancy Serious infections Kidney graft
  thrombosis Hepatic artery thrombosis
  Nephrotoxicity Hyperlipemia Angioedema
  Interstitial lung disease Thrombocytopenia
  Male infertility Proteinuria New commencement
  of diabetes .

14
DRUG INTERACTION

•  Everotas 10mg interaction with strong inhibitor
  of CYP3A4, or P-gp, leads to cause decreasing the
  efflux of Everolimus and increase the plasma
  concentration of Everolimus. Combination
  of Everotas 10mg with verapamil leads to
  increasing the plasma concentration of
  Everolimus. Combination of Everotas 10mg with
  Atorvastatin or pravastatin causes
  rhabdomyolysis, due to increasing concentration
  of lipid lowering agents. Everotas
  10mg combination with strong CYP3A4 inducers,
  causes increasing the exposure of Everolimus.
  Concomitant use of Everotas 10mg with
  cyclosporine causes increasing the AUC level of
  Everolimus frequently. Everotas 10mg tablet is
  interaction with ketoconazole or other CYP3A4
  inhibitors causes increasing the plasma
  concentration and AUC of Everolimus.
  Concomitant use with erythromycin causes
  increasing in AUC of Everolimus.

15
CONTRAINDICATIONS

• Some anaphylactic reaction occurs, if patients
  are contraindicated to the components present in
  the Everotas 10mg tablet.

16
PREGNANCY

• Pregnancy category C Everotas 10mg is needed only
  by the patients after knowing the benefits to the
  mother outweighs the risk to fetus.

17
STORAGE

• Everotas 10mg tablet should be kept at 25CKeep
  the tablet away from moisture, heat and
  lightDispense only in original container.

18
MISSED DOSE

• If patient failed to take a single dose, patients
  must consult with medical practitioner and follow
  the instructions given by them. Or the missed
  dose should be avoiding and follow the regular
  dosing schedule.

19
OVERDOSAGE

• The over dosage of Everolimus is rarely occur, in
  case of over dosage patient must be provide with
  supportive measures. The acute toxicity of
  Everolimus over dosage should be monitored.

20
CONTACT US

• PHONE NO 91-9940472902
• EMAIL millionhealthpharmaceuticals_at_gmail.com
• WEBSITEURLhttps//millionpharma.com/everotas-10-m
  g.php

21
(No Transcript)